New Jersey-based Immunomedics has developed a novel antibody drug conjugate (ADC) platform centred around its specialised hydrolysable linker, which delivers...
Read More...
The post Immunomedics Q&A: using ADCs to tackle unmet needs in breast cancer appeared first on Pharmaceutical Technology.
Original Article: Immunomedics Q&A: using ADCs to tackle unmet needs in breast cancer